Terns Pharmaceuticals
Terns Pharmaceuticals
TERN
NASDAQ
3.18
USD
0.00%
About
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501.
TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases.
TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.0M |
| Three Month Average Volume | 26.3M |
| High Low | |
| Fifty-Two Week High | 10.03 USD |
| Fifty-Two Week Low | 3.26 USD |
| Fifty-Two Week High Date | 16 Jul 2024 |
| Fifty-Two Week Low Date | 10 Nov 2023 |
| Price and Volume | |
| Current Price | 7.62 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -3.31% |
| Thirteen Week Relative Price Change | 18.46% |
| Twenty-Six Week Relative Price Change | -5.20% |
| Fifty-Two Week Relative Price Change | 15.39% |
| Year-to-Date Relative Price Change | -0.85% |
| Price Change | |
| One Day Price Change | -0.78% |
| Thirteen Week Price Change | 26.79% |
| Twenty-Six Week Price Change | 4.24% |
| Five Day Price Change | -7.30% |
| Fifty-Two Week Price Change | 44.59% |
| Year-to-Date Price Change | 17.41% |
| Month-to-Date Price Change | -1.68% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 3.95447 USD |
| Book Value Per Share (Most Recent Quarter) | 3.10911 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 3.95447 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 3.10911 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.47452 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.26594 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.31275 USD |
| Normalized (Last Fiscal Year) | -1.26594 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.26594 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.31275 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.26594 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.31275 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 4.07949 USD |
| Cash Per Share (Most Recent Quarter) | 3.20317 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.26184 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.30604 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.08065 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -25,651 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -30,820.50% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -32,166.90% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -31,010.30% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 4.46% |
| Tangible Book Value (5 Year) | 28.73% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -26.60% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -21.76% |
| EPS Change (Trailing Twelve Months) | -2.22% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -225,297,000 |
| Net Debt (Last Fiscal Year) | -263,440,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 22 |
| Current Ratio (Most Recent Quarter) | 21 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -67,442,000 |
| Free Cash Flow (Trailing Twelve Months) | -79,086,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -32.48% |
| Return on Assets (Trailing Twelve Months) | -36.84% |
| Return on Assets (5 Year) | -41.34% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -33.89% |
| Return on Equity (Trailing Twelve Months) | -38.92% |
| Return on Equity (5 Year) | -86.48% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -33.72% |
| Return on Investment (Trailing Twelve Months) | -38.72% |
| Return on Investment (5 Year) | -45.70% |